New hope for rare cancers: drug trial targets hard-to-treat tumors
NCT ID NCT05337735
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 26 times
Summary
This study tests a drug called XmAb20717 in 140 adults with advanced rare cancers, including mesothelioma, cervical cancer, and Hodgkin's lymphoma. The goal is to see if the drug can shrink tumors and how safe it is. Participants must have measurable disease and be able to follow the study plan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.